Infliximab and leflunomide combination therapy in rheumatoid arthritis: an open-label study.

@article{Kiely2002InfliximabAL,
  title={Infliximab and leflunomide combination therapy in rheumatoid arthritis: an open-label study.},
  author={Patrick D. W. Kiely and David M Johnson},
  journal={Rheumatology},
  year={2002},
  volume={41 6},
  pages={631-7}
}
OBJECTIVE To study the safety and efficacy of infliximab plus leflunomide combination therapy in adult rheumatoid arthritis (RA). METHODS Twenty patients with active RA received leflunomide 100 mg for 3 days followed by 20 mg daily for 32 weeks. At week 2 all patients started infliximab 3 mg/kg, and received a further four infusions at weeks 4, 8, 16 and 24. RESULTS Adverse events led to 11 patients being withdrawn before the end of the study. The commonest adverse event was pruritus… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 21 extracted citations

TNF alpha antagonist therapy and safety monitoring.

Joint, bone, spine : revue du rhumatisme • 2011

Infliximab in the treatment of rheumatoid arthritis

Biologics : targets & therapy • 2009
View 1 Excerpt

Similar Papers

Loading similar papers…